Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug

Cristiana Perrotta; Paolo Pellegrino; Eliana Moroni; Clara De Palma; Davide Cervia; Piergiorgio Danelli; Emilio Clementi

doi:10.1155/2015/456895

Gastroenterology Research and Practice (Jan 2015)

Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug

Cristiana Perrotta,
Paolo Pellegrino,
Eliana Moroni,
Clara De Palma,
Davide Cervia,
Piergiorgio Danelli,
Emilio Clementi

Affiliations

Cristiana Perrotta: Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy
Paolo Pellegrino: Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy
Eliana Moroni: Unit of General Surgery, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy
Clara De Palma: Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy
Davide Cervia: Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy
Piergiorgio Danelli: Unit of General Surgery, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy
Emilio Clementi: Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, Italy

DOI: https://doi.org/10.1155/2015/456895
Journal volume & issue: Vol. 2015

Abstract

Read online

Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn’s disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.

Published in Gastroenterology Research and Practice

ISSN: 1687-6121 (Print); 1687-630X (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
Website: https://www.hindawi.com/journals/grp/

About the journal